Q3 2024 EPS Estimates for KALA BIO, Inc. Increased by HC Wainwright (NASDAQ:KALA)

KALA BIO, Inc. (NASDAQ:KALA) – Investment analysts at HC Wainwright increased their Q3 2024 earnings estimates for shares of KALA BIO in a note issued to investors on Wednesday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($2.15) for the quarter, up from their previous estimate of ($4.17). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for KALA BIO’s current full-year earnings is ($14.49) per share. HC Wainwright also issued estimates for KALA BIO’s Q4 2024 earnings at ($2.15) EPS, FY2024 earnings at ($10.94) EPS, Q1 2025 earnings at ($2.34) EPS, Q2 2025 earnings at ($1.77) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.42) EPS and FY2025 earnings at ($6.67) EPS.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.40) by $1.24.

KALA BIO Trading Up 1.7 %

NASDAQ:KALA opened at $5.85 on Friday. The stock has a market capitalization of $16.47 million, a price-to-earnings ratio of -0.39 and a beta of -2.03. KALA BIO has a 1 year low of $4.21 and a 1 year high of $14.50. The stock has a fifty day moving average price of $6.46 and a two-hundred day moving average price of $6.90. The company has a debt-to-equity ratio of 4.92, a quick ratio of 4.22 and a current ratio of 4.22.

Insider Activity

In related news, CEO Mark T. Iwicki sold 7,392 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $6.09, for a total value of $45,017.28. Following the completion of the transaction, the chief executive officer now directly owns 278,923 shares of the company’s stock, valued at approximately $1,698,641.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other KALA BIO news, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total transaction of $72,048.00. Following the completion of the transaction, the chief executive officer now owns 263,755 shares in the company, valued at $1,252,836.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Mark T. Iwicki sold 7,392 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $6.09, for a total transaction of $45,017.28. Following the completion of the sale, the chief executive officer now directly owns 278,923 shares in the company, valued at approximately $1,698,641.07. The disclosure for this sale can be found here. Insiders sold 35,255 shares of company stock worth $182,564 in the last 90 days. 13.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO as of its most recent SEC filing. Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.